ATON

MKT CAP:$729059

AlphaTON Capital Corp.

Market Cap

$729059

Financial Services·Asset Management·🇺🇸 United States·NASDAQ

Financials·Asset Management·🇺🇸·NASDAQ

Stock Price

$0.32-$0.45 (-58.19%)

Apr 20, 2026

Company Details

AlphaTON Capital Corp. is the rebranded entity formerly known as Portage Biotech Inc., a clinical-stage immuno-oncology company transitioning into a digital asset treasury model focused on accumulating and staking Toncoin (TON). AlphaTON in...

CEO

Brittany Kaiser

IPO Date

Jan 2, 2002

Website

www.portagebiotech.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$20M

EPS (Diluted)

-$7.04

Free Cash Flow

-$4M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q2 2026

Jan 12, 2026

$0EPS -$4.13

Q1 2026

Jun 30, 2025

$0EPS -$2.57

FY 2025

Jul 25, 2025

$0EPS -$5.72

Q4 2025

Jul 25, 2025

$0EPS -$0.17

Q3 2025

Dec 31, 2024

$0EPS -$0.17

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 18	$0	$0	-$1M
Q1 19	$0	$0	-$164.0K
Q2 19	$0	$0	-$193.0K
Q1 21	$0	$0	-$973.0K
Q3 23	$0	$0	-$5M
Q4 23	$0	$0	-$4M
Q1 24	$0	$0	-$5M
Q2 24	$0	$0	-$6M
Q3 24	$0	$0	-$4M
Q4 24	$0	$0	-$3M
Q1 25	$0	$0	-$3M
Q2 25	$0	$0	-$2M
Q3 25	$0	$0	-$1M
Q4 25	$0	$0	-$1M
Q1 26	$0	$0	-$3M
Q2 26	$0	$0	-$5M

Valuation

Quarter	P/S	P/E
Q4 18	—	3.6x
Q1 19	—	5.9x
Q2 19	—	4.5x
Q1 21	—	19.8x
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—
Q1 26	—	—
Q2 26	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 19	-$185.0K	-$185.0K
Q2 19	-$187.0K	-$187.0K
Q1 21	-$688.0K	-$688.0K
Q4 21	-$995.4K	-$995.4K
Q3 23	-$3M	-$3M
Q4 23	-$5M	-$5M
Q1 24	-$3M	-$3M
Q2 24	-$4M	-$4M
Q3 24	-$3M	-$3M
Q4 24	-$3M	-$3M
Q1 25	-$2M	-$2M
Q2 25	-$2M	-$2M
Q3 25	-$1M	-$1M
Q4 25	-$1M	-$1M
Q1 26	-$715.0K	-$715.0K
Q2 26	-$715.0K	-$715.0K

Capital Expenditures

Quarter	CapEx
Q1 19	$0
Q2 19	$0
Q1 21	$0
Q4 21	$3
Q3 23	$75
Q4 23	$43
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0
Q1 26	$0
Q2 26	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 18	—	+572.0%
Q1 19	—	+150.5%
Q2 19	—	+158.0%
Q1 21	—	+383.7%
Q3 23	—	+288.2%
Q4 23	—	+2385.4%
Q1 24	—	+2489.1%
Q2 24	—	+509.5%
Q3 24	—	-15.4%
Q4 24	—	-20.3%
Q1 25	—	-43.2%
Q2 25	—	-73.0%
Q3 25	—	-63.5%
Q4 25	—	-54.7%
Q1 26	—	+8.6%
Q2 26	—	+180.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 19	$9.0K	—
Q2 19	$4.0K	—
Q1 21	$296.0K	—
Q4 21	$8M	—
Q3 23	$1M	—
Q4 23	$662.0K	—
Q1 24	$769.0K	—
Q2 24	$743.0K	—
Q3 24	$736.0K	—
Q4 24	$389.0K	—
Q1 25	$144.0K	—
Q2 25	$141.0K	—
Q3 25	$307.5K	—
Q4 25	$307.5K	—
Q1 26	$517.0K	—
Q2 26	$984.0K	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 18	$72.0K	$1M
Q1 19	$61.0K	$94.0K
Q2 19	$65.0K	$94.0K
Q1 21	$452.0K	$521.0K
Q3 23	$3M	$2M
Q4 23	$2M	$2M
Q1 24	$4M	$1M
Q2 24	$4M	$2M
Q3 24	$3M	$1M
Q4 24	$2M	$1M
Q1 25	$1M	$2M
Q2 25	$723.0K	$881.0K
Q3 25	$550.5K	$919.5K
Q4 25	$550.5K	$919.5K
Q1 26	$647.5K	$2M
Q2 26	$578.0K	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 17	$7M	$0	$7M
Q2 17	$467.5K	$0	$467.5K
Q3 17	$252.1K	$0	$252.1K
Q4 17	$159.4K	$59M	$59M
Q4 18	$8M	$52.0K	$8M
Q1 19	$7M	$79.0K	$7M
Q2 19	$7M	$75.0K	$7M
Q3 19	$6M	$74.0K	$6M
Q3 24	$5M	$0	$5M
Q4 24	$5M	$0	$5M
Q1 25	$3M	$0	$3M
Q2 25	$2M	$0	$2M
Q3 25	$2M	$0	$2M
Q4 25	$2M	$0	$2M
Q1 26	$2M	$0	$2M
Q2 26	$183.0K	$0	$183.0K

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 18	3M	-5.6%	+4.5%
Q1 19	3M	+6.7%	+7.9%
Q2 19	3M	-0.1%	+0.4%
Q1 21	11M	+293.4%	+295.7%
Q3 23	17M	+53.4%	+543.5%
Q4 23	18M	+3.3%	+523.1%
Q1 24	18M	+0.5%	+527.1%
Q2 24	18M	+0.6%	+60.3%
Q3 24	21M	+17.4%	+22.6%
Q4 24	20M	-5.3%	+12.4%
Q1 25	11M	-43.1%	-36.4%
Q2 25	11M	0.0%	-36.8%
Q3 25	11M	0.0%	-46.1%
Q4 25	11M	0.0%	-43.1%
Q1 26	2M	-80.7%	-80.7%
Q2 26	3M	+15.5%	-77.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 18	—	—
Q1 19	—	—
Q2 19	—	—
Q1 21	$0	10K
Q3 23	$0	6
Q4 23	$0	7
Q1 24	$0	7
Q2 24	$0	7
Q3 24	$0	7
Q4 24	$0	7
Q1 25	$0	7
Q2 25	$0	7
Q3 25	$0	7
Q4 25	$0	3
Q1 26	$0	3
Q2 26	$0	3

Revenue / Employee